Showing posts with label FTC consent order. Show all posts
Showing posts with label FTC consent order. Show all posts

Tuesday, May 18, 2010





FTC Approves Combination of Scientific Equipment Manufacturers

This posting was written by Jeffrey May, Editor of CCH Trade Regulation Reporter.

Agilent Technologies Inc., a supplier of scientific measurement instruments, closed it acquisition of medical device and software maker Varian, Inc. on May 14, after the parties entered into a proposed FTC consent order.

Under the terms of the proposed consent order, the companies agreed to sell three product lines in order to resolve FTC antitrust concerns over their combination.

According to the FTC's complaint, with the divestitures, Agilent's acquisition of Varian would have violated U.S. antitrust laws by reducing competition for three types of scientific measurement instruments in which the companies competed with one another.

The companies competed in the markets for the production and sale of micro gas chromatography instruments (Micro GCs), triple quadrupole gas chromatography-mass spectrometry instruments (3Q GC-MS), and inductively coupled plasma-mass spectrometry (ICP-MS) instruments.

The FTC contended that in each market, without the proposed divestitures, the acquisition would have allowed Agilent to raise prices, decrease innovation, or reduce customer service. According to the complaint, Agilent and Varian were the only two competitors producing Micro GCs, and the acquisition would leave Agilent with a monopoly in that market.

Similarly, in the 3Q GC-MS and ICP-MS markets, there are currently only four competing firms. Eliminating the competition between Agilent and Varian would leave Agilent with a post-merger market share of nearly 50 percent in each market.

With the closing of the deal, which "brings together two Silicon Valley pioneers," Agilent was now positioned as a leading provider of analytical instrumentation to the applied and life sciences markets, the company said in a May 14 statement.

The complaint and proposed consent order, In the Matter of Agilent Technologies, Inc., FTC File No. 0910135, announced May 14, 2010, are available on the FTC website. Further details will appear in CCH Trade Regulation Reporter.

Monday, November 02, 2009





FTC, Canada Competition Bureau Approve Schering-Plough’s Acquisition of Merck

This posting was written by Jeffrey May, Editor of CCH Trade Regulation Reporter.

Schering-Plough Corporation can proceed with its proposed $41.1 billion acquisition of Merck & Co. Inc. under the terms of a proposed FTC consent order, according to the agency's October 29 announcement.

The consent order would settle FTC charges that the transaction, as originally proposed, could have reduced competition in a range of animal health markets in which the companies compete and in the market for human drugs known as NK 1 receptor antagonists, which are used to treat nausea and vomiting resulting from chemotherapy and surgery.

The companies are two of the leading animal health suppliers in the United States. According to the FTC, the proposed acquisition raised significant concerns in markets where Merck—through Merial Limited, an animal health joint venture with Sanofi-Aventis S.A—and Schering-Plough directly compete. Merck would be required to sell its interest in Merial, under the proposed consent order.

In the market for NK 1 receptor antagonists, Merck’s Emend was the first and only approved treatment for human use. Schering-Plough, however, was in the process of licensing its own NK 1 receptor antagonist, rolapitant, to a third party when the company’s acquisition of Merck was announced.

The transaction, therefore, likely would have reduced the combined firm’s incentives to launch rolapitant, delaying or eliminating a future entrant into the market for NK 1 receptor antagonist drugs for nausea and vomiting. Under the terms of the FTC’s consent order, Schering-Plough would be required to sell assets related to rolapitant.

Canada Competition Bureau Approval

Canada's Competition Bureau also announced on October 29 that it has reached an agreement with Merck and Schering-Plough to resolve competition concerns with respect to their proposed merger. The Competition Bureau said that it worked closely with the FTC in its investigation. The relief imposed by the Competition Bureau is the same as that which would be required under the proposed FTC consent order.

The complaint and proposed consent order, In the Matter of Schering-Plough Corporation, a corporation, and Merck & Co. Inc., FTC Docket No. C-4268, will appear at CCH Trade Regulation Reporter ¶16,383.